Literature DB >> 33783822

Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges.

Kevin Ten Haaf1, Carlijn M van der Aalst1, Harry J de Koning1, Rudolf Kaaks2,3, Martin C Tammemägi4.   

Abstract

Randomised clinical trials have shown the efficacy of computed tomography lung cancer screening, initiating discussions on whether and how to implement population-based screening programs. Due to smoking behaviour being the primary risk-factor for lung cancer and part of the criteria for determining screening eligibility, lung cancer screening is inherently risk-based. In fact, the selection of high-risk individuals has been shown to be essential in implementing lung cancer screening in a cost-effective manner. Furthermore, studies have shown that further risk-stratification may improve screening efficiency, allow personalisation of the screening interval and reduce health disparities. However, implementing risk-based lung cancer screening programs also requires overcoming a number of challenges. There are indications that risk-based approaches can negatively influence the trade-off between individual benefits and harms if not applied thoughtfully. Large-scale implementation of targeted, risk-based screening programs has been limited thus far. Consequently, questions remain on how to efficiently identify and invite high-risk individuals from the general population. Finally, while risk-based approaches may increase screening program efficiency, efficiency should be balanced with the overall impact of the screening program. In this review, we will address the opportunities and challenges in applying risk-stratification in different aspects of lung cancer screening programs, as well as the balance between screening program efficiency and impact.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.

Entities:  

Keywords:  lung cancer screening; personalised screening; risk-based screening

Year:  2021        PMID: 33783822     DOI: 10.1002/ijc.33578

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Impact of Smoking History on Pulmonary Metastasis-free Survival in Patients With Soft-tissue Sarcoma.

Authors:  Masatake Matsuoka; Masanori Okamoto; Tamotsu Soma; Isao Yokota; Ryuta Arai; Tomohiro Onodera; Eiji Kondo; Norimasa Iwasaki; Hiroaki Hiraga
Journal:  Cancer Diagn Progn       Date:  2021-05-03

Review 2.  Implementing Lung Cancer Screening in Europe: Taking a Systems Approach.

Authors:  Suzanne Wait; Arturo Alvarez-Rosete; Tasnime Osama; Dani Bancroft; Robin Cornelissen; Ante Marušić; Pilar Garrido; Mariusz Adamek; Jan van Meerbeeck; Annemiek Snoeckx; Olivier Leleu; Ebba Hallersjö Hult; Sébastien Couraud; David R Baldwin
Journal:  JTO Clin Res Rep       Date:  2022-04-22

3.  Lung function impairment in the German Lung Cancer Screening Intervention Study (LUSI): prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality.

Authors:  Rudolf Kaaks; Evangelia Christodoulou; Erna Motsch; Verena Katzke; Mark O Wielpütz; Hans-Ulrich Kauczor; Claus Peter Heussel; Monika Eichinger; Stefan Delorme
Journal:  Transl Lung Cancer Res       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.